MedTrace Logo

Non Invasive IDentification of Gliomas With IDH1 Mutation

NCT01703962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2021-08-26

No results posted yet for this study

Summary

The recurrent mutation IDH1Arg132His leads to the cellular accumulation of D-2-hydroxyglutarate (2-HG), thus representing a diagnostic marker (this change is almost specific for gliomas) and prognostic (mutated gliomas have longer survival) of interest.

The main objective is to identify the patients with IDH1 mutated glioma by three complementary approaches -genetic (identification of IDH1 mutation in plasmatic DNA), biochemical (2-HG dosage in the urine of patients) and radiological (2-HG

Conditions

  • Non Invasive Diagnosis of Glioma

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Marc SANSON, MDPhD · University of Pittsburgh

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-14
Primary Completion
2014-03-31
Completion
2014-03-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01703962 on ClinicalTrials.gov